|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
depletes B cells
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:1997
gptkb:FDA
|
|
gptkbp:average_temperature
|
2-8 ° C
|
|
gptkbp:brand
|
gptkb:Rituxan
|
|
gptkbp:can_be_used_with
|
gptkb:methotrexate
chemotherapy
corticosteroids
|
|
gptkbp:class
|
gptkb:vaccine
|
|
gptkbp:clinical_trial
|
Phase III
maintenance therapy
induction therapy
|
|
gptkbp:contraindication
|
active infections
severe hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rituximab
|
|
gptkbp:indication
|
autoimmune diseases
|
|
gptkbp:ingredients
|
C6424 H9924 N1716 O1980 S44
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
gptkb:non-Hodgkin_lymphoma
gptkb:rheumatoid_arthritis
|
|
gptkbp:manager
|
IV
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
half-life 19 days
|
|
gptkbp:research
|
gptkb:musician
gptkb:healthcare_organization
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:Sjogren's_syndrome
gptkb:psychologist
gptkb:Insurance_Company
gptkb:systemic_sclerosis
gptkb:ankylosing_spondylitis
gptkb:psoriatic_arthritis
gptkb:dermatomyositis
psoriasis
solid tumors
chronic inflammatory demyelinating polyneuropathy
hemophagocytic lymphohistiocytosis
idiopathic thrombocytopenic purpura
|
|
gptkbp:side_effect
|
fatigue
nausea
cardiovascular events
skin reactions
infections
hypotension
infusion reactions
pulmonary toxicity
tumor lysis syndrome
hepatitis B reactivation
|
|
gptkbp:targets
|
C D20
|
|
gptkbp:weight
|
143 k Da
|
|
gptkbp:bfsParent
|
gptkb:healthcare_organization
gptkb:castle
|
|
gptkbp:bfsLayer
|
3
|